DJIA 17,265.99 109.14 0.64%
NASDAQ 4,593.43 31.24 0.68%
S&P 500 2,011.36 9.79 0.49%
market minute promo


45.35 -0.66 (-1.43%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

CLVS $45.35 -1.43%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $46.14
Previous Close $46.01
Daily Range $44.50 - $46.41
52-Week Range $35.33 - $93.33
Market Cap $1.5B
P/E Ratio -12.96
Dividend (Yield) $0.00 (0.0%)
Volume 661,934
Average Daily Volume 776,042
Current FY EPS -$4.20




Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets. Website:

News & Commentary

Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals

Clovis Oncology and Sunesis Pharmaceuticals are facing pivotal catalysts for their experimental cancer drugs. Which company offers the better risk-to-reward ratio?

Clovis Oncology (CLVS) CEO Pat Mahaffy Presents at Morgan Stanley Healthcare Conference (Transcript)

Clovis Oncology (CLVS) Falls: Stock Goes Down 6.8% - Tale of the Tape

CLVS January 2016 Options Begin Trading

Sector Update: Health-Care Stocks Mixed Pre-Market

Competition And Momentum Weighing On Clovis Oncology

Top Swing Trade Ideas for Monday, August 11: Coach, Clovis Oncology, More

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q2 2014 Results - Earnings Call Transcript

Biotech Enters Reporting Season With Large Caps Central To Sector Performance

3 Stocks Tumbling This Month: Clovis Oncology, Hyperion Therapeutics, and Puma Biotechnology

Puma Biotechnology (PBYI), Clovis Oncology (CLVS), and Hyperion Therapeutics (HPTX) all stumbled by more than 10% in June.

See More CLVS News...